Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

Bibliographic Details
Main Authors:	Renato Centrone, Marcelo Bellesso, Debora Bonito, Daniela Dias, Rodrigo Santucci, Milton Aranha, Adelson Alves
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137919301622

Similar Items

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
by: Ronan Swords, et al.
Published: (2009-03-01)

Nilotinib therapy in an imatinib intolerant chronic myeloid leukemia patient with pulmonary severe hypertension
by: Mario Annunziata
Published: (2015-10-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
by: Giuliana Alimena, et al.
Published: (2008-10-01)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01)

Successful Peripheral Blood Stem Cells Collection in Imatinib Pretreated and Nilotinib-Treated Chronic Myeloid Leukemia Patient
by: Samuel Vokurka, et al.
Published: (2010-01-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene
by: Marcelo Bellesso, et al.
Published: (2013-06-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

Nilotinib therapy after resistance to imatinib
by: Raffaele Porrini, et al.
Published: (2015-10-01)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
by: Mealing Stuart, et al.
Published: (2013-02-01)

Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib
by: Fausto Palmieri
Published: (2015-10-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
by: Mario Annunziata
Published: (2015-10-01)

Development and targeted use of nilotinib in chronic myeloid leukemia
by: Carmen Fava, et al.
Published: (2008-11-01)

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
by: Yoo Jin Na, et al.
Published: (2021-03-01)

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
by: E Loveman, et al.
Published: (2012-05-01)

Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
by: Hassan A. Al-Jafar, et al.
Published: (2015-03-01)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
by: David L DeRemer, et al.
Published: (2011-03-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
by: G Rogers, et al.
Published: (2012-04-01)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
by: Massimo Breccia, et al.
Published: (2017-10-01)

Different response to imatinib and nilotinib in relationship with the time of administration
by: Paolo Danise
Published: (2015-10-01)

Nilotinib and Imatinib Utilization in Iran over 14 years
by: Ava Mansouri, et al.
Published: (2020-12-01)

A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy
by: Ayda Bennour, et al.
Published: (2013-03-01)

Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
by: Vihang Patel, et al.
Published: (2017-05-01)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
by: Piccaluga PP, et al.
Published: (2012-11-01)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
by: Shunsuke Maruta, et al.
Published: (2021-08-01)

SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS
by: I. V. Dmytrenko, et al.
Published: (2019-07-01)

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.
by: Fiorenzo Santoleri, et al.
Published: (2013-01-01)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
by: Husam N. Al-Dubai, et al.
Published: (2020-06-01)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
by: Alauldeen Mudhafar Zubair Alqasim, et al.
Published: (2019-01-01)